Clinical Studies

Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

This study will compare certain markers in the blood that are specific to cancer, but not found in healthy dogs, before and after surgical biopsy or surgical removal of a mass.

This study will compare markers in the blood that are specific to cancer but not found in healthy dogs, before and after treatment for cancer has begun.

Single Day Clinic: March 7, 2020.

Ethos Discovery is pursuing an investigation into the use of a novel therapy for NME in pugs. This study will only consist of a one-time visit for the blood sample collection. Participating pugs will get free wellness and neurological exams, general bloodwork, and NME-risk factor screening.

The goal of this study is to evaluate changes in procalcitonin levels over time in canine patients surgically treated for sepsis secondary to an abdominal cause (i.e. ruptured intestine). Additional blood sample collection will also be performed to investigate for possible novel markers for sepsis using next generation sequencing for the future development of diagnostic test.

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. To date, no studies have been published investigating the intestinal microbiome in dogs or humans with osteosarcoma (OSA). The objective of this study is to determine whether or not canine patients diagnosed with OSA have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

This is study is looking to develop a novel diagnostic test for canine pancreatitis through the identification of genomic markers called exosomes.